CTOs on the Move

Sutro Biopharma

www.sutrobio.com

 
At Sutro Biopharma, a clinical stage company, we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer therapeutics and autoimmune disease — Antibody Conjugates, Bispecific Antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sutrobio.com
  • 310 Utah Avenue Suite 150
    South San Francisco, CA USA 94080
  • Phone: 650.392.8412

Executives

Name Title Contact Details

Funding

Sutro Biopharma raised $144.9M on 12/14/2020

Similar Companies

Apertus Pharmaceuticals

API Manufacturing Company

Homecure

Homecure is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Nature`s Bounty Corporation

The Nature`s Bounty Co. has a history of championing health and wellness tracing back 145 years. Putting science and the highest quality standards at the heart of our business, the brands of The Nature`s Bounty Co. are some of the most trusted in the world. Always motivated by our commitment to excellence, our vision for health and wellness has inspired leading brands such as Nature`s Bounty, Sundown Naturals, Solgar, Holland & Barrett, Osteo Bi-Flex, Ester-C, MET-Rx, Pure Protein, Balance, Body Fortress, Puritan`s Pride and Organic Dr., among others. As a leading global manufacturer, marketer, distributor and retailer of vitamins, nutritional supplements, sports & active nutrition and ethical beauty products, The Nature`s Bounty Co. is committed to supporting wellness in all its forms.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.

Nanōmix

Nanōmix is the leader in mobile point-of-care diagnostics for use where time and accuracy is critical.